| Literature DB >> 33386253 |
Tariq Chukir1, Lindsay Mandel2, Beverly G Tchang3, Nada A Al-Mulla4, Leon I Igel3, Rekha B Kumar3, Jonathan Waitman3, Louis J Aronne3, Alpana P Shukla5.
Abstract
It is unknown whether weight loss outcomes differ with metformin monotherapy in patients with obesity with or without type 2 diabetes (T2DM)/prediabetes (PreDM). In this retrospective study, 6- or 12-month weight loss outcomes were compared in 222 patients with or without T2DM/preDM who completed metformin monotherapy. Average weight loss was similar between groups, euglycemic vs. T2DM/preDM (6 months: 6.5 [6.0%] vs. 6.5 [6.1%] p = 0.97; 12 months: 7.4 [6.2%] vs. 7.3 [7.7%], p = 0.92). Categorical weight losses (≥5% and ≥10% of baseline weight) were also similar. Comparable clinically significant weight loss was achieved with metformin monotherapy in patients with obesity with or without T2DM/PreDM.Entities:
Keywords: Metformin; Obesity; Type 2 diabetes; Weight loss; Weight management
Year: 2020 PMID： 33386253 DOI： 10.1016/j.orcp.2020.12.005
Source DB: PubMed Journal: Obes Res Clin Pract ISSN： 1871-403X Impact factor: 2.288